455 related articles for article (PubMed ID: 36365206)
1. Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology.
Amanat M; Nemeth CL; Fine AS; Leung DG; Fatemi A
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365206
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Sang A; Zhuo S; Bochanis A; Manautou JE; Bahal R; Zhong XB; Rasmussen TP
BioDrugs; 2024 Jun; ():. PubMed ID: 38914784
[TBL] [Abstract][Full Text] [Related]
3. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides in neurological disorders.
Wurster CD; Ludolph AC
Ther Adv Neurol Disord; 2018; 11():1756286418776932. PubMed ID: 29854003
[TBL] [Abstract][Full Text] [Related]
5. Making sense of antisense oligonucleotides: A narrative review.
Goyal N; Narayanaswami P
Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
[TBL] [Abstract][Full Text] [Related]
6. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
7. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
Barresi V; Musmeci C; Rinaldi A; Condorelli DF
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides: the next frontier for treatment of neurological disorders.
Rinaldi C; Wood MJA
Nat Rev Neurol; 2018 Jan; 14(1):9-21. PubMed ID: 29192260
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic antisense oligonucleotides for movement disorders.
Doxakis E
Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
Hammond SM; Abendroth F; Gait MJ; Wood MJA
Methods Mol Biol; 2019; 2036():221-236. PubMed ID: 31410800
[TBL] [Abstract][Full Text] [Related]
11. Medicinal Chemistry of Antisense Oligonucleotides for Therapeutic Use in SARS-CoV-2: Design Strategies and Challenges for Targeted Delivery.
Nedaeinia R; Ranjbar M; Goli M; Etebari M; Safabakhsh S; Bayram H; Ferns GA; Tehrani HM; Salehi R
Curr Med Chem; 2024 Jun; ():. PubMed ID: 38860908
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
Shadid M; Badawi M; Abulrob A
Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotides: A primer.
Scoles DR; Minikel EV; Pulst SM
Neurol Genet; 2019 Apr; 5(2):e323. PubMed ID: 31119194
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.
Verma A
Ann Indian Acad Neurol; 2018; 21(1):3-8. PubMed ID: 29720791
[TBL] [Abstract][Full Text] [Related]
15. Chemistry, structure and function of approved oligonucleotide therapeutics.
Egli M; Manoharan M
Nucleic Acids Res; 2023 Apr; 51(6):2529-2573. PubMed ID: 36881759
[TBL] [Abstract][Full Text] [Related]
16. Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides.
McNally EM; Leverson BD
J Clin Invest; 2019 Nov; 129(11):4570-4571. PubMed ID: 31566581
[TBL] [Abstract][Full Text] [Related]
17. [Gene-specific treatment approaches in muscle diseases].
Lehmann Urban D; Schneider I
Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
[TBL] [Abstract][Full Text] [Related]
18. Drug Discovery Perspectives of Antisense Oligonucleotides.
Kim Y
Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides and other genetic therapies made simple.
Rossor AM; Reilly MM; Sleigh JN
Pract Neurol; 2018 Apr; 18(2):126-131. PubMed ID: 29455156
[TBL] [Abstract][Full Text] [Related]
20. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Monine M; Norris D; Wang Y; Nestorov I
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
